Global Biosimilar Monoclonal Antibodies Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Biosimilar Monoclonal Antibodies Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
Biosimilar Monoclonal Antibodies report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biosimilar Monoclonal Antibodies market is projected to reach US$ 12960 million in 2034, increasing from US$ 4509.2 million in 2022, with the CAGR of 16.0% during the period of 2024 to 2034. Demand from Oncology and Autoimmune Disease are the major drivers for the industry.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biosimilar Monoclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Oncology
Autoimmune Disease
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Biosimilar Monoclonal Antibodies market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Biosimilar Monoclonal Antibodies, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Biosimilar Monoclonal Antibodies industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Biosimilar Monoclonal Antibodies in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Biosimilar Monoclonal Antibodies introduction, etc. Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Biosimilar Monoclonal Antibodies market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
Biosimilar Monoclonal Antibodies report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biosimilar Monoclonal Antibodies market is projected to reach US$ 12960 million in 2034, increasing from US$ 4509.2 million in 2022, with the CAGR of 16.0% during the period of 2024 to 2034. Demand from Oncology and Autoimmune Disease are the major drivers for the industry.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biosimilar Monoclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Biosimilar Monoclonal Antibodies market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Biosimilar Monoclonal Antibodies, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Biosimilar Monoclonal Antibodies industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Biosimilar Monoclonal Antibodies in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Biosimilar Monoclonal Antibodies introduction, etc. Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Biosimilar Monoclonal Antibodies market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices